Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07453888 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
A Phase 3 study, sponsored by Dompé Farmaceutici S.p.A.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
NCT07453888 is a Phase 3 study that is actively recruiting participants, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 272 participants.
The verdict
NCT07453888, a Phase 3 study, is actively recruiting participants, sponsored by Dompé Farmaceutici S.p.A.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
Study Summary
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION. Approximately 272 participants who meet all eligibility criteria will be randomly assigned in a 1:1 ratio to receive either cenegermin treatment (Group 1) or the vehicle control (Group 2).
Interventions
- OTHER Vehicle
- DRUG Cenegermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07453888
The ClinicalTrials.gov registry entry for NCT07453888 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT07453888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07453888 about?
NCT07453888 is a clinical study titled "Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)". This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION. Approximately 272 participants who meet all eligibility criteria will be randomly assigned ...
What is the current status of trial NCT07453888?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2026-06-30. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07453888?
The interventions under investigation include: Vehicle (OTHER), Cenegermin (DRUG).
Who is sponsoring clinical trial NCT07453888?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.